Affordable Access

Publisher Website

Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin

Authors
Journal
European Journal of Cancer and Clinical Oncology
0277-5379
Publisher
Elsevier
Publication Date
Volume
21
Issue
10
Identifiers
DOI: 10.1016/0277-5379(85)90013-6

Abstract

Abstract Thirteen patients were treated with both the oral and intravenous preparations of 4-demethoxydaunorubicin (DMDR). The drug was well tolerated in both forms. Neutropenia was the dose-limiting side-effect. Approximately 30% of the compound was absorbed when given orally. The maximum tolerated dose was 12.5 mg/m 2 intravenously or 50 mg/m 2 (10 mg/m 2 q d × 5) orally, given every 21–28 days.

There are no comments yet on this publication. Be the first to share your thoughts.